2. Search Result
Search Result
Results for "

calcification

" in MedChemExpress (MCE) Product Catalog:

26

Inhibitors & Agonists

1

Screening Libraries

1

Peptides

6

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W015370
    L-Lysine hydrate
    5 Publications Verification

    		 Endogenous Metabolite Others Inflammation/Immunology
    L-Lysine hydrate is an essential amino acid. L-Lysine hydrate can be research for vascular calcification (VC) and acute pancreatitis .
    L-Lysine hydrate
  • HY-14210
    TNAP-IN-1

    		Phosphatase Inflammation/Immunology
    TNAP-IN-1 (Compound 1) is a selective tissue-nonspecific alkaline phosphatase (TNAP) inhibitor, with an IC50 of 0.19 μM. TNAP-IN-1 can be used for the research of soft tissue calcification .
    TNAP-IN-1
  • HY-B0302
    Etidronic acid
    1 Publications Verification

    Etidronate; HEDPA; HEDP

    		 Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) is an orally and intravenously active bisphosphonate. Etidronic acid inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid has anticancer activity. Etidronic acid is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid
  • HY-126304
    β-Glycerophosphate disodium salt hydrate
    Maximum Cited Publications
    7 Publications Verification

    		 Phosphatase Endogenous Metabolite ERK Metabolic Disease
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
    β-Glycerophosphate disodium salt hydrate
  • HY-D0886
    β-Glycerophosphate disodium salt pentahydrate
    Maximum Cited Publications
    7 Publications Verification

    		 Phosphatase Endogenous Metabolite ERK Metabolic Disease Cancer
    β-Glycerophosphate disodium salt pentahydrate is a bioactive endogenous metabolite and a phosphatase inhibitor. β-Glycerophosphate disodium salt pentahydrate plays an important role in inducing and maintaining osteoblast differentiation, mineral metabolism and signal transduction, and can be used as a drug carrier to form heat-sensitive hydrogels. β-Glycerophosphate disodium salt hydrate accelerates the calcification of vascular smooth muscle cells .
    β-Glycerophosphate disodium salt pentahydrate
  • HY-103265
    ARL67156 trisodium
    2 Publications Verification

    FPL 67156 trisodium

    		 NTPDase Cardiovascular Disease Inflammation/Immunology
    ARL67156 (FPL 67156) trisodium is a selective small molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma .
    ARL67156 trisodium
  • HY-W014606
    L-Lysine acetate

    		Endogenous Metabolite Others Inflammation/Immunology
    L-Lysine acetate is an essential amino acid. L-Lysine acetate can be research for vascular calcification (VC) and Acute pancreatitis .
    L-Lysine acetate
  • HY-W014606R
    L-Lysine acetate (Standard)

    		Endogenous Metabolite Others Inflammation/Immunology
    L-Lysine (acetate) (Standard) is the analytical standard of L-Lysine (acetate). This product is intended for research and analytical applications. L-Lysine acetate is an essential amino acid. L-Lysine acetate can be research for vascular calcification (VC) and Acute pancreatitis .
    L-Lysine acetate (Standard)
  • HY-138822
    2,3-Diphospho-D-glyceric acid pentasodium salt

    2,3-DPG pentasodium salt

    		 Others Cardiovascular Disease
    2,3-Diphospho-D-glyceric acid pentasodium salt is a highly anionic polyphosphorus compound. 2,3-Diphospho-D-glyceric acid is present in the concave center of red blood cells, it binds hemoglobin to reduce its oxygen affinity. 2,3-Diphospho-D-glyceric acid is an endogenous, selective inhibitor of vascular calcification (VC) and significantly delays the formation of crystalline calpain particles (CPP). 2,3-Diphospho-D-glyceric acid also inhibits calcification in mouse vascular smooth muscle cell line (MOVAS) without cytotoxic effects .
    2,3-Diphospho-D-glyceric acid pentasodium salt
  • HY-116307
    2-Thio-UTP

    		P2Y Receptor Cardiovascular Disease
    2-Thio-UTP is a selective P2Y2 inhibitor with an EC50 value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .
    2-Thio-UTP
  • HY-103265B
    ARL67156 trisodium hydrate
    2 Publications Verification

    FPL 67156 trisodium hydrate

    		 NTPDase Cardiovascular Disease Inflammation/Immunology
    ARL67156 (FPL 67156) trisodium hydrate is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium hydrate is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma .
    ARL67156 trisodium hydrate
  • HY-103265D
    ARL67156 triethylamine
    2 Publications Verification

    FPL 67156 triethylamine

    		 NTPDase Cardiovascular Disease Inflammation/Immunology
    ARL67156 (FPL 67156) triethylamine is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 triethylamine is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with Kis of 11, 18 and 12?μM, respectively. ARL67156 triethylamine can be used in the research of disease like calcific aortic valve disease, asthma .
    ARL67156 triethylamine
  • HY-114616
    PBB3

    		Others Neurological Disease
    PBB3, a selective PET ligand, recognizes tau pathology in Alzheimer's disease brains, where dystrophic neurites and diffuse neurofibrils are more clearly detected Tangles with calcification .
    PBB3
  • HY-B0561
    Spironolactone
    3 Publications Verification

    SC9420

    		 Mineralocorticoid Receptor Androgen Receptor Autophagy Calcium Channel Cardiovascular Disease Metabolic Disease Endocrinology Cancer
    Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (AngⅡ)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type Ⅱ diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca 2+ channels to exert antihypertensive effects .
    Spironolactone
  • HY-B0302A
    Etidronic acid disodium
    1 Publications Verification

    Etidronate disodium; HEDPA disodium; HEDP disodium

    		 Apoptosis Metabolic Disease Cancer
    Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid disodium
  • HY-119093
    Halopemide

    		Phospholipase Dopamine Receptor Neurological Disease Cancer
    Halopemide is a potent phospholipase D (PLD) inhibitor, with IC50s of 220 and 310 nM for human PLD1 and PLD2, respectively. Halopemid is a dopamine receptors antagonist, and acts a psychotropic agent .
    Halopemide
  • HY-108611
    AACOCF3
    3 Publications Verification

    Arachidonyl trifluoromethyl ketone

    		 Phospholipase Cardiovascular Disease
    AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease .
    AACOCF3
  • HY-120657
    9-PAHSA

    		Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology
    9-PAHSA is an orally available anti-inflammatory lipid that lowers blood sugar and reduces inflammation. 9-PAHSA also improved carotid vascular calcification and attenuates cardiac hypertrophy and dysfunction in db/db mice. 9-PAHSA increases the viability of steatosis primary mouse hepatocytes (PMH). 9-PAHSA can be used in research on diabetes, inflammation, and cardiovascular disease .
    9-PAHSA
  • HY-B0302AR
    Etidronic acid disodium (Standard)

    		Apoptosis Metabolic Disease Cancer
    Etidronic acid (disodium) (Standard) is the analytical standard of Etidronic acid (disodium). This product is intended for research and analytical applications. Etidronic acid (Etidronate) disodium is an orally and intravenously active bisphosphonate. Etidronic acid disodium inhibits resorption of bone, reduces arterial calcification and can be used for osteoporosis research. Etidronic acid disodium has anticancer activity. Etidronic acid disodium is a chelating agent and can be used to remove heavy metal in water .
    Etidronic acid disodium (Standard)
  • HY-153335
    Enpp-1-IN-16

    		Phosphodiesterase (PDE) Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Enpp-1-IN-16 (compound 54) is an ENPP1 inhibitor. Enpp-1-IN-16 has the potential to study cancer, especially in cases of high ENPP1 expression or elevated cytoplasmic DNA levels. Enpp-1-IN-16 can also be used in other diseases mediated by ENPP1, such as bacterial or viral infections, insulin resistance and type II diabetes, chondrocalcinosis and osteoarthritis, calcium pyrophosphate deposition disorder (CPPD), low Phosphatase disease and soft tissue calcification disorders .
    Enpp-1-IN-16
  • HY-112499
    Menaquinone-7
    1 Publications Verification

    Vitamin K2-7; Vitamin K2(35); Vitamin MK-7

    		 Others Cardiovascular Disease
    Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7
  • HY-135517
    RXP470.1

    RXP-470

    		 MMP Cardiovascular Disease
    RXP470.1 (RXP-470) is a potent, selective MMP-12 inhibitor with a Ki of 0.2 nM against human MMP-12. RXP470.1 is 2 to 4 orders of magnitude less potent against other MMPs. RXP470.1 significantly reduces atherosclerotic plaque cross-sectional area in mouse. RXP470.1 results in less complex plaques with increased smooth muscle cell:macrophage ratio, less macrophage apoptosis, increased cap thickness, smaller necrotic cores, and decreased incidence of calcification .
    RXP470.1
  • HY-112499S
    Menaquinone-7-d7

    Vitamin K2-7-d7; Vitamin K2(35)-d7; Vitamin MK-7-d7

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors[1]. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins [2]. Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS)[3].
    Menaquinone-7-d7
  • HY-112499S1
    Menaquinone-7-13C6

    Vitamin K2-7-13C6; Vitamin K2(35)-13C6; Vitamin MK-7-13C6

    		 Isotope-Labeled Compounds Cardiovascular Disease
    Menaquinone-7- 13C6 is the 13C-labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors[1]. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins [2]. Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS)[3].
    Menaquinone-7-13C6
  • HY-112499R
    Menaquinone-7 (Standard)

    Vitamin K2-7(Standard); Vitamin K2(35)(Standard); Vitamin MK-7 (Standard)

    		 Others Cardiovascular Disease
    Menaquinone-7 (Standard) is the analytical standard of Menaquinone-7. This product is intended for research and analytical applications. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs (orally active), is originally discovered as the anti-hemorrhagic factors. Menaquinone-7 inhibits osteoclast bone resorption in vitro and stimulates bone formation in femoral tissue of aged female rats. Menaquinone-7 has a well-researched potential in the prevention of aging-induced bone degeneration. Menaquinone-7 is also a pharmacological option for activating Gla matrix protein and intervening in the progression of calcific aortic stenosis (CAVS) .
    Menaquinone-7 (Standard)
  • HY-P0109
    (S,S)-Z-FA-FMK

    		Cathepsin Others
    (S,S)-Z-FA-FMK is a cell-permeable, irreversible cathepsin B inhibitor. (S,S)-Z-FA-FMK blocks LPS-induced production of IL-1α and IL-1β. (S,S)-Z-FA-FMK can be used as a negative control for caspase-1 and caspase-2 inhibitors because it lacks an aspartic acid residue at the P1 position .
    (S,S)-Z-FA-FMK

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: